SCHEMBL5145404

SCHEMBL5145404

O=C1NC(=O)C(=C(Cc2ccc(F)cc2)c2ccc(-c3ccc(C(=O)O)cc3)o2)N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.43
PTPN1 P18031 1/20 0.42
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 5/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
BCL2L1 Q07817 1/20 0.40
BAD Q92934 1/20 0.40
SLC9A1 P19634 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
NQO2 P16083 1/20 0.39
INSR P06213 1/20 0.38
IGF1R P08069 1/20 0.38
TDP1 Q9NUW8 4/20 0.38
MAPT P10636 2/20 0.38
APEX1 P27695 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145398 1.00 ENPP2 (0.43) ENPP2PTPN1ALDH1A1KDM4ELMNA
SCHEMBL5147466 0.84 MEN1 (0.44) ALDH1A1KDM4ETDP1MAPTAPEX1
SCHEMBL5146594 0.84 ALDH1A1 (0.55) PTPN1ALDH1A1KDM4ETDP1MAPT
SCHEMBL5147288 0.72 GSK3B (0.44) ALDH1A1KDM4EHPGDGSK3AGSK3B
SCHEMBL5181927 0.71 SIRT2 (0.46) PTPN1ALDH1A1KDM4ELMNAHPGD
SCHEMBL5145012 0.71 MEN1 (0.42) ALDH1A1KDM4ETDP1MAPTL3MBTL1
SCHEMBL5143420 0.70 PIM1 (0.46) ALDH1A1KDM4EGSK3AGSK3BTDP1
SCHEMBL3054179 0.69 ALDH1A1 (0.70) PTPN1ALDH1A1KDM4ELMNAHPGD
SCHEMBL5145369 0.68 PTPN1 (0.43) ENPP2PTPN1ALDH1A1KDM4ELMNA
SCHEMBL5146624 0.65 MEN1 (0.69) KDM4EGSK3AGSK3BINSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 ENPP2 411/4885PTPN1 2566/4885ALDH1A1 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.